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In the vasculature, NADPH oxidase is the main contributor of reactive oxygen species (ROS) which play a key role in endothelial
signalling and functions. We demonstrate that ECV304 cells express p47phox, p67phox, and p22phox subunits of NADPH oxidase, as
well as formyl peptide receptors 1 and 3 (FPR1/3), which are members of the GPCR family. By RT-PCR, we also detected Flt-1 and
Flk-1/KDR in these cells. Stimulation of FPR1 by N-fMLP induces p47phox phosphorylation, which is the crucial event for NADPH
oxidase-dependent superoxide production. Transphosphorylation of RTKs by GPCRs is a biological mechanism through which the
information exchange is ampliﬁed throughout the cell. ROS act as signalling intermediates in the transactivation mechanism. We
show that N-fMLP stimulation induces the phosphorylation of cytosolic Y951, Y996, and Y1175 residues of VEGFR2, which
constitute the anchoring sites for signalling molecules. These, in turn, activate PI3K/Akt and PLC-γ1/PKC intracellular
pathways. FPR1-induced ROS production plays a critical role in this cross-talk mechanism. In fact, inhibition of FPR1 and/or
NADPH oxidase functions prevents VEGFR2 transactivation and the triggering of the downstream signalling cascades. N-fMLP
stimulation also ameliorates cellular migration and capillary-like network formation ability of ECV304 cells.
1. Introduction
Vascular endothelial growth factor receptor 2 (VEGFR2)/
Flk-1/KDR and VEGFR1/Flt1 are members of the receptor
tyrosine kinase (RTK) family and bind to vascular endothe-
lial growth factor (VEGF) promoting organization, migra-
tion, proliferation, and formation of vascular structures of
endothelial cells (ECs) [1]. In the human VEGFR2, Y951,
Y1054, Y1059, Y1175, and Y1214 residues have been
detected as phosphorylation sites [2, 3] and Y801, Y996,
and Y1008 residues have been involved in VEGFR2 signalling
[4, 5]. The phosphorylated Y1175 residue binds to phospho-
lipase Cγ (PLC-γ) [3], as well as with the adaptor molecules
Shb [6] and Sck [7], whereas the phosphorylated Y951 resi-
due mediates binding for VEGF receptor-associated protein
(VRAP), which is also known as a T cell-speciﬁc adapter
(TSAd), which is crucial for EC migration in vitro and cell
actin reorganization [2]. The phosphorylated Y1214 residue
of VEGFR2 represents an anchoring site for the adaptor
protein Nck [8], whereas the role of the phosphorylation
of Y1224, Y1305, Y1309, and Y1319 residues in the C-
terminal tail still remains to be determined.
The G protein-coupled receptors (GPCRs) are a super-
family of plasma membrane proteins activated by several
ligands. Their agonist-speciﬁc stimulation induces G protein
dissociation and, in turn, the activation of membrane-
associated enzymes, intracellular second messengers, or ion
channels. The human formyl peptide receptors 1, 2, and 3
(FPR1, FPR2, and FPR3) are members of the GPCR family
and are all associated with pertussis toxin- (PTX-) sensitive
Gi proteins [9–11]. FPR1 binds to eﬃciently N-formyl-
methionyl-leucyl-phenylalanine (N-fMLP), whereas FPR2
is eﬀectively activated by low concentrations of WKYMVm
peptide [12]. The signiﬁcant biological functions of FPR1
and FPR2 are supported by the discovery of high-aﬃnity
host-derived ligands. These two receptors are expressed in
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several cell types [13, 14], whereas FPR3, which does not
bind to N-fMLP or WKYMVm, is expressed in mono-
cytes, dendritic cells [9–11], and human umbilical vein
endothelial cell (HUVEC) primary cultures [15]. FPR2 is
also expressed on nuclear membranes of human lung car-
cinoma CaLu-6 and human gastric adenocarcinoma AGS
cell lines [16, 17].
The most important source of ROS in ECs is NADPH
oxidase, which consists of cytosolic subunits p47phox,
p40phox, p67phox, and the small GTPase Rac1 and of
membrane-associated proteins p22phox and gp91phox. In sev-
eral cell types, FPR stimulation by N-fMLP or WKYMVm
induces superoxide generation as a consequence of MEK-
and PKC-dependent phosphorylation of the regulatory
subunit p47phox, which is in large part prevented by prein-
cubation with PTX [13, 18–20]. NADPH oxidase-derived
ROS act as intracellular second messengers by activating
several redox signalling cascades implicated in VEGFR2
autophosphorylation, EC migration, angiogenesis, prolifera-
tion [21], and postnatal angiogenesis in vivo [22]. Neverthe-
less, molecular mechanisms responsible for NADPH oxidase
activation and the function of ROS in redox signalling
linked to angiogenesis remain unclear.
Even though GPCRs are deﬁcient of an intrinsic tyrosine
kinase activity, binding of speciﬁc ligands may induce
tyrosine phosphorylation of RTKs. The agonist-dependent
stimulation of GPCRs can enhance the signalling activity of
RTKs, linking the ample heterogeneity of GPCRs with the
eﬀective signalling abilities of RTKs. Transactivation of
RTKs by GPCRs may occur by diverse molecular mecha-
nisms, which include the activation of metalloexopeptidases
and metalloendopeptidases, the involvement of nonreceptor
tyrosine kinases associated with the membrane, or NADPH
oxidase-dependent ROS generation [23]. In diﬀerent cell
types, FPR2 stimulation prompts phosphorylation of tyro-
sine residues of EGFR, which provide anchoring sites for
the recruitment and activation of intracellular signalling
pathways [24], and HGF receptor transphosphorylation,
thereby inducing part of the molecular responses trig-
gered by c-Met/HGF binding [19]. ROS play a crucial
role in these cross-talk mechanisms since the inhibition
of NADPH oxidase functions prevents EGFR and c-Met
transactivation [19, 24].
Herein, we show that ECV304 cells express FPR1,
Flk-1/KDR, and p47phox and that FPR1 stimulation by
N-fMLP induces NADPH oxidase-dependent ROS gener-
ation as well as the transphosphorylation of cytosolic
Y951, Y996, and Y1175 residues of VEGFR2. These phos-
photyrosines represent anchoring sites for signalling mol-
ecules that, in turn, activate PI3K/Akt and PLC-γ1/PKC
intracellular pathways involved in cell attachment and cell
migration of ECs. Furthermore, FPR1 activation also
ameliorates cellular migration and capillary-like network
formation of ECV304 cells.
2. Materials and Methods
2.1. Antibodies and Chemicals. The N-fMLP peptide was syn-
thesized and HPLC-puriﬁed by PRIMM (Milan, Italy). SDS-
PAGE reagents were purchased from Bio-Rad (Hercules, CA,
USA). Protein A/G Plus, anti-Flk1, anti-p-Flk1 (Tyr951),
anti-p-Flk1 (Tyr996), anti-p-Flk1 (Tyr1175), anti-p-Flk1
(Tyr1214), anti-p-Tyr, anti-p47phox, anti-p22phox, anti-p-
PLCγ1 (Y783), anti-PLCγ1, anti-PKCα, anti-PKCβII, anti-
PKCζ, anti-PKCδ, anti-tubulin, anti-mouse, and anti-rabbit
were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-p-PI3K (p85) and anti-p-Akt (Ser473) were from
Cell Signaling Technology (Danvers, MA, USA). Anti-p-Ser,
p22phox siRNA (SI03078523), and scramble control siRNA
(SI03650318) were from Qiagen (Hiden, Germany). FPR1
siRNA (L-005140-00) and scramble control (D-001810-10)
were purchased from Dharmacon (Lafayette, CO, USA).
Protein A-horseradish peroxidase was from Amersham
Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK).
Pertussis toxin (PTX), apocynin, wortmannin, and LY294002
were from Sigma (St. Louis, MO, USA).
2.2. RNA Puriﬁcation and RT-PCR Analysis. Total RNA was
puriﬁed from ECV304 cells by TRIzol reagents (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instruc-
tion, and 0.1μg of RNA was used as a template for reverse
transcription experiments, as previously described [25].
Primer sequences designed to amplify human coding regions
and relative product sizes are reported in Table 1.
2.3. Cell Culture. ECV304 cells (ATCC®CRL-1998) were
obtained from ATCC (Rockville, MD, USA) and were grown
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS), 100U/ml penicillin, and
100μg/ml streptomycin. Cells were serum-starved for 24
hours, once they reached 80% of conﬂuence, and then stim-
ulated with 0.1μM N-fMLP peptide for various times, as
reported in the ﬁgures. In other experiments, serum-starved
cells were preincubated with 100ng/ml PTX for 16 hours,
50μM LY294002 for 1 hour, 0.5μM wortmannin for 1 hour,
or 100μM apocynin for 2 hours, before stimulation with
0.1μMN-fMLP for 5 minutes. Short interfering RNA exper-
iments were performed incubating 4× 105 cells with 5 nM
siRNAs for 12 hours, in DMEM containing 10% FBS and
20μl of HiPerFect (Qiagen, Hiden, Germany). Cells were
then serum-starved for 24 hours and stimulated with
0.1μM N-fMLP for 5 minutes. ECV304 cells were also incu-
bated with 20ng/ml VEGF, as a control.
2.4. Western Blotting and Immunoprecipitation Assays.
ECV304 cells were incubated with N-fMLP with or without
speciﬁc inhibitors as described above. Whole lysates were
puriﬁed in buﬀer containing 150mmol/l NaCl, 50mmol/l
Tris-HCl (pH8.5), 2mmol/l EDTA, 1% v/v NP-40, 0.5%
w/v deoxycholate, 10mmol/l NaF, 10mM sodium pyro-
phosphate, 2mmol/l PMSF, 2μg/ml leupeptin, and 2μg/
ml aprotinin (pH7.4), as previously described [26]. Lysates
were incubated at 0°C for 15min and then centrifuged at
38000×g for 15min at 4°C. Puriﬁcation of membrane
proteins was performed as previously described [19]. Bio-
Rad protein assay (Bio-Rad, Hercules, CA, USA) was used
to determine protein concentration. Proteins were resolved
on a 10% SDS-PAGE, and immunoblot experiments were
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performed as previously described [24]. Immunoprecipita-
tion experiments were performed by incubating equal
amounts of proteins with 3μg of anti-p47phox or anti-
Flk1 antibodies. Protein expression or phosphorylation
was detected by the ECL chemiluminescence reagent kit
(Amersham Pharmacia Biotech) and visualized by autora-
diography. Densitometry analysis was used to quantify
protein or phosphorylation levels by using a Discover
Pharmacia scanner.
2.5. Superoxide Production Assay. Membranes and cytosol
fractions were puriﬁed from serum-starved ECV304 cells
stimulated with 0.1μM N-fMLP for the times reported in
the ﬁgure. The reduction of cytochrome c was measured
to determine NADPH-dependent superoxide generation, as
previously described [24]. Brieﬂy, 10μg of membrane pro-
teins and 200μg of cytosolic proteins were incubated in
PBS in the presence of 15μM GTP-γ-S, 100μM cytochrome
c, and 10μM FAD in a ﬁnal volume of 1ml. Superoxide
production was monitored at 550nm, after the addition of
100μM NADPH. Cells were also incubated with 200U/ml
superoxide dismutase (SOD), as the control of the speciﬁcity
of cytochrome c reduction. Superoxide anion generation
was measured as the SOD-inhibitable reduction of ferricy-
tochrome c. Individual treatments were compared with the
values obtained from growth-arrested ECV304 cells by
Student’s t-test.
2.6. Cell Migration Assay. ECV304 cells were grown as
described above until they reached 100% conﬂuence, and a
wound was induced in the monolayer by scratching it with
a sterile 80μm diameter tip. Cells were incubated in serum-
deprived medium at 37°C at 5% CO2, and time-lapse images
were taken every 12 hours up to 36 hours after wound gener-
ation by using the Leica AF6000 Modular System and proc-
essed by using the Leica LAS AF light software. The
covered surface was quantiﬁed with the ImageJ software.
2.7. Capillary-Like Network Formation. 48-multiwell plates
were coated with 150μL of Matrigel (BD Bioscience) per
well and then allowed to polymerize for 30 minutes at
37°C, according to the manufacturer’s instructions. 1× 105
ECV304 cells, pretreated or not with 100ng/ml PTX, were
plated in the precoated wells with serum-free DMEM in the
presence or absence of 0.1μM N-fMLP or 20 ng/ml VEGF
(Gold Biotechnology, Olivette, USA) for 16 hours at 37°C.
Network formation was acquired with the Leica AF6000
Modular System, and the total tube length was measured by
using the ImageJ software.
2.8. Statistical Analysis. All the reported data are expressed as
means± SD and represent at least three unrelated experi-
ments. Statistical analyses were evaluated by Student’s t-test,
and their signiﬁcance was considered with a minimum value
Table 1: Forward and reverse PCR primer sequences.
Primers Primer sequence Product size
β-Actin
5′-TGATCACCATTGGGAATGAG-3′
154 bp
5′-CAGTGTGTTGGCGTAGAGGT-3′
Flk-1/KDR
5′-GAGGGCCACTCATGGTGATTG-3′
709 bp
5′-TGCCAGCAGTCCAGCATGGTCTG-3′
Flt-1
5′-GAGAATTCACTATGGAAGATCTGATTTCTTACAGT-3′
498 bp
5′-GAGCATGCGGATAAATACACATGTGCTTCTAG-3′
Flt-4
5′-CCCACGCAGACATCAAGACG-3′
380 bp
5′-TGCAGAACTCCACGATCACC-3′
FPR1
5′-GACCACAGCTGGTGAACAGT-3′
474 bp
5′-GATGCAGGACGCAAACACAG-3′
FPR2
5′-GGATTTGCACCCACTGCATTT-3′
528 bp
5′-ATCCAAGGTCCGACGATCAC-3′
FPR3
5′-GAGTTGCTCCACAGGAATCCA-3′
760 bp
5′-ATAGGCACGCTGAAGCCAAT-3′
p47phox
5′-GGTGGGTCATCAGGAAAGAC-3′
210 bp
5′-GCAGAAAACGGACGCTGTTG-3′
p22phox
5′-TGTGCCTGCTGGAGTACCCC-3′
441 bp
5′-ACACGACCTCGTCGGTCACC-3′
p67phox
5′-GCCAGGTGAAAAACTACTGC-3′
246 bp
5′-CTTCCAGCCATTCTTCATTC-3′
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of p < 0 05. All statistical analyses were performed with the
Prism statistical software.
3. Results and Discussion
3.1. ECV304 Cells Express Flt-1, Flk-1/KDR, NADPH
Oxidase, and a Functional FPR1 Receptor. ECV304 cells
were initially described as a HUVEC-derived transformed
cell line [27], but they were later characterized, by genetic
relationship, as a cell line derived from human urinary blad-
der carcinoma T24 cells [28]. Nevertheless, although not of
HUVEC origin, ECV304 cells show many characteristics
of ECs [29, 30] and present both epithelial and endothelial
features [31], a number of which are solely endothelial
markers and consequently not detected in T24 cells [30].
Therefore, ECV304 cells seem to be a relevant model for
the study of molecular mechanisms in the endothelium, such
as signal transduction, cell migration, and capillary-like
network formation.
In these cells, we detected, by RT-PCR, the expression of
Flt-1 and Flk-1/KDR (Figure 1(a)), but not of Flt-4, which is
expressed only in lymphatic endothelial cells. The two VEGF
receptors were also detected by immunostaining in ECV304
cells [32]. We also analyzed the expression of FPRs, and we
provided the ﬁrst evidence that FPR1 and FPR3 but not
FPR2 (Figure 1(b)) are expressed in ECV304 cells. This cell
line also expresses p47phox, p67phox, and p22phox subunits of
the NADPH oxidase enzymatic complex (Figure 1(c)). In
human ﬁbroblasts, stimulation of FPRs with N-fMLP
induces p47phox phosphorylation, which is the crucial event
required for NADPH oxidase activation [13]. In ECV304
cells, FPR1 is a functional receptor; in fact, stimulation with
0.1μM N-fMLP triggers time-dependent phosphorylation
of p47phox (Figure 1(d)) which is entirely inhibited by prein-
cubation with PTX (Figure 1(e)). Furthermore, incubation
with N-fMLP for diﬀerent times stimulates NADPH
oxidase-dependent superoxide production, with a maximum
of ROS generation occurring at 6min (Figure 1(f)).
3.2. FPR1 Stimulation by N-fMLP Promotes Flk-1/KDR
Transactivation. Cellular eﬀects of VEGF-A on ECs, such as
permeability, migration, survival, and proliferation, are
mediated by Flk-1/KDR, which binds VEGF-A to the second
and third extracellular Ig-like domains. This allows the cor-
rect placement of the intracellular kinase domains, which
results in the Flk-1/KDR autophosphorylation [33].
Cross-talk between GPCRs and RTKs modulates
downstream signalling pathways involved in many biological
functions of mammalian cells [19, 23, 24, 34]. Therefore, we
analyzed Flk-1/KDR transactivation by FPR1 in ECV304
cells, and in Western blot experiments, we noticed that
the incubation with 0.1μM N-fMLP increases Flk-1/KDR
tyrosine phosphorylation in a time-dependent manner
(Figure 2(a)). VEGFR2 is the main signal transducer in
ECs, and in the human Flk-1/KDR intracellular domain,
multiple tyrosine residues have been detected as phosphory-
lation sites, including Y801, Y951, Y996, Y1008, Y1054,
Y1059, Y1175, and Y1214 [2–4]. The FPR1 agonist triggers
the phosphorylation of Y951, Y996, and Y1175 residues
of Flk-1/KDR within the ﬁrst 5min (Figure 2(b)), which
is completely inhibited by preincubating ECV304 cells with
PTX before N-fMLP exposure (Figure 2(c)). A signiﬁcant
reduction in the phosphorylation levels of Y951, Y996,
and Y1175 residues is observed when cells are preincu-
bated with siRNAs against FPR1 before N-fMLP treatment
(Figure 2(d)), indicating that VEGFR2 transphosphorylation
is mediated by FPR1.
3.3. Flk-1/KDR Transactivation Depends on NADPH
Oxidase-Dependent ROS Generation. The main source of
ROS in the arterial wall and ECs is NADPH oxidase [35],
which can be activated by several stimuli including GPCR
agonists [23, 36]. In nonphagocytic cells, NADPH oxidase
expression depends on the cellular types and surrounding
conditions and produces ROS at low levels [21, 23], which
can act as signalling molecules by reversible oxidation/reduc-
tion of cysteines located in the catalytic site of protein tyro-
sine phosphatases (PTPs) [19, 21, 37, 38]. ROS can play a
role in RTK transphosphorylation by preventing the PTPase
action and, in turn, changing the RTK from a nonphosphory-
lated to a phosphorylated state. A number of PTPs, such as
LMW-PTP (HCPTPA), SHP-1, and SHP-2, are associated
with Flk-1/KDR upon VEGF stimulation [39, 40]. We prein-
cubated ECV304 cells with apocynin (Figure 3(a)), which
speciﬁcally inhibits NADPH oxidase, or with a siRNA against
p22phox (Figure 3(b)), an essential component of the
membrane-associated NADPH oxidase, and we noticed that
the FPR1-induced transphosphorylation of Y951, Y996, and
Y1175 residues of Flk-1/KDR is prevented by the arrest of
NADPH oxidase functions (Figures 3(a) and 3(b)). These
results demonstrate that FPR1-mediated superoxide genera-
tion feeds the cross-talk between FPR1 and Flk-1/KDR.
3.4. FPR1-Induced Flk-1/KDR Transactivation Triggers the
PI3K/Akt Pathway. Phosphorylated tyrosine residues of
Flk-1/KDR represent anchoring sites for signalling molecules
that trigger intracellular pathways, which, in turn, activate
biological responses such as cell proliferation and migration
[41]. In the human VEGFR2, several phospho-tyrosines have
been identiﬁed [1–4] and so far Y951, Y996, Y1054, Y1059,
Y1175, and Y1214, in the kinase insert domain, in the kinase
domain, and in the C-terminal tail of VEGFR2, have been
deﬁned as the main autophosphorylation sites [42]. Phos-
phorylation of Y1175, within the pYIVL sequence, provides
a docking site for several signalling molecules, including
PLC-γ [3] and the adaptor proteins Sck [7] and Shb [6].
Shb contains an SH2 and a PTB domain, four presumed tyro-
sine phosphorylation sites, and a proline-rich N-terminus
motif [6]. Shb binds to phospho-tyrosine Y1175 of VEGFR2,
resulting in its Src-dependent phosphorylation [6]. Shb-
dependent binding to the Y1175 residue is important for
the PI3K response, but it is unclear how this eﬀect is pursued.
The SH3 domain of PI3K (p85) could interact with Shb at the
level of the proline-rich motif; otherwise, the eﬀect could be
mediated by focal adhesion kinase (FAK), which is involved
in cellular attachment and migration [43]. Silencing of Shb
by small interfering RNA (siRNA) results in the arrest of
PI3K activation.
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The phosphorylated Y951 residue in the VEGFR2 kinase
insert domain binds to TSAd which is equivalent to Rlk- and
Itk-binding protein (RIBP), Lck adaptor (LAD), and VRAP
[44]. Y951-mediated binding between VEGFR2 and TSAd
plays a critical role in cell migration of ECs and VEGF-
induced actin reorganization. In fact, site-directed mutagen-
esis of Y951 to F951 in Flk1/KDR, or silencing by siRNA of
VRAP/TSAd expression, prevents VEGFA-mediated migra-
tion [2]. Stimulated RTKs typically activate PI3K by inducing
phosphorylation of a tyrosine residue within an YXXM
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Figure 1: ECV304 cells express Flk-1/KDR, FPR1, and NADPH oxidase. Total RNA was puriﬁed from ECV304 cells. cDNA was coampliﬁed
by using (a) Flk-1/KDR (lane 1), Flt-1 (lane 2), or Flt-4 (lane 3); (b) FPR1 (lane 1), FPR2 (lane 2), or FPR3 (lane 3); and (c) p47phox (lane 1),
p67phox (lane 2), p22phox (lane 3), or β-actin primers. PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide.
(d) Serum-starved ECV304 cells were stimulated with 0.1 μM N-fMLP for the indicated times or (e) preincubated with PTX before N-fMLP
stimulation for 5 minutes. Whole lysates (1mg) were immunoprecipitated with an α-p47phox antibody and resolved on 10% SDS-PAGE.
p47phox phosphorylation was determined by using an α-p-Ser antibody. An α-p47phox antibody served as a control for protein loading. (f)
Superoxide production was determined as a SOD-sensitive rate reduction of cytochrome c in serum-starved ECV304 cells stimulated
or not with 0.1μM N-fMLP for the indicated times. All the experiments are representative of at least three independent experiments.
∗p < 0 05 compared with unstimulated cells.
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motif, which represents an anchoring site for SH2 domains of
the p85 regulatory subunit of PI3K. Binding of PI3K to the
YXXM motif mediates Akt activation. Phosphorylation of
the tyrosine residue is mediated by TSAd, which activates
members of Src family kinases [45, 46]. Flk-1/KDR does
not have a pYXXM motif detected by the SH2 domain of
the p85 subunit [47]; nevertheless, a binding site for the
p85 subunit of PI3K is localized in the Gab1 adaptor protein,
which also binds to VEGFR2, although the exact binding site
in the receptor is unknown [48, 49].
In ECs, VEGFA-induced cell survival depends on Flk-1/
KDR and on the consequent activation of PI3K and Akt,
which induces A1 and Bcl-2 expression [50]. We analyzed
PI3K activation in N-fMLP-stimulated ECV3014 cells, and
in Western blot experiments, we detected that N-fMLP stim-
ulates PI3K (p85) phosphorylation in a time-dependent man-
ner (Figure 4(a)). This is prevented by pretreating EVC304
cells with PTX or apocynin (Figure 4(b)), suggesting that
PI3K (p85) phosphorylation depends on PTX-sensible GPCR
and NADPH oxidase-dependent superoxide generation.
Activation of PI3K and production of phos-
phatidylinositol (3,4,5)-trisphosphate (PIP3) result in the
consequent activation of Akt by PDK1 and PDK2, which
phosphorylate Akt at T308 and S473 residues, respectively.
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Figure 2: FPR1 activation promotes Flk-1/KDR transphosphorylation. (a) Whole lysates (900 μg) puriﬁed from serum-starved ECV304 cells
stimulated with 0.1μM N-fMLP for the indicated times were immunoprecipitated with an α-Flk-1 antibody, and Flk-1 tyrosine
phosphorylation was detected with an α-pY antibody. An α-Flk1 antibody served as a control for protein loading. (b, c, d) Fifty
micrograms of whole lysates, puriﬁed from ECV304 cells, was resolved on 10% SDS-PAGE. The cells were (b) stimulated with N-fMLP
for the indicated times, (c) stimulated with N-fMLP for 5 minutes in the presence or absence of PTX, or (d) incubated for 12 hours with
5 nM siRNA against FPR1 (FPR1 siRNA) or negative control siRNA (NC siRNA) in DMEM containing 10% FBS in the presence of 20μl
of HiPerfect. The ﬁlters were immunoblotted with α-pFlk-1 (Y951), α-pFlk-1 (Y996), α-pFlk-1 (Y1175), or α-pFlk-1 (Y1214) antibodies.
An α-Flk-1 antibody served as a control for protein loading. ∗p < 0 05 compared with unstimulated cells. °p < 0 05 compared with
unstimulated cells. #p < 0 05 compared with unstimulated cells.
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We analyzed Akt phosphorylation in FPR1-stimulated
ECV304 cells, and we observed that N-fMLP induces Akt
(S473) phosphorylation in the same time interval of PI3K
(p85) phosphorylation (Figure 4(c)). Akt (S473) phosphory-
lation is prevented by preincubation of ECV304 cells with
selective PI3K inhibitors (Figure 4(d)), as well as with PTX,
which blocks FPR1-bound Gi proteins in their inactive form,
or with apocynin (Figure 4(e)). The critical role of FPR1 and
NADPH oxidase in the Akt (Ser473) phosphorylation is sup-
ported by the ﬁnding that preincubation with siRNAs against
FPR1 (Figure 4(f)) or against p22phox (Figure 4(g)) before
N-fMLP treatment results in a substantial decrease in the
phosphorylation levels of Akt.
3.5. FPR1-Mediated Phosphorylation of the Y1175 Residue
Provides a Docking Site for PLC-γ1 Activation. The phos-
phorylated Y1175 residue of Flk-1/KDR represents a binding
site for PLC-γ1 [3] and other adaptor proteins [6, 7]. PLC-γ1
is phosphorylated and its catalytic activity is enhanced as a
consequence of binding to pY1175. PLC-γ plays a crucial role
in angiogenesis, as demonstrated by the observation that
PLC-γ1-deﬁcient mouse embryos die at nearly E9.0 with sub-
stantially reduced erythropoiesis and vasculogenesis [51, 52]
and that the mutation of Y1173 in mice (Y1175 in human) is
responsible for the embryonic mortality at E8.5–9.5, as a con-
sequence of anomalies of haematopoietic and endothelial
cells [53]. Furthermore, in zebraﬁsh, PLC-γ1 is required for
arterial development, as demonstrated by the observation
that zebraﬁsh embryos lacking in PLC-γ1 do not respond
to VEGF [54]. These results support the idea that signalling
from pY1175 of VEGFR2 to the PLC-γ/PKC pathway is
essential for vasculogenesis in embryogenesis.
Four activation-induced tyrosine phosphorylation sites
(Y472, Y771, Y783, and Y1254) have been described in
PLC-γ1 [55]. In time-course experiments, we observed
that N-fMLP induces PLC-γ1 activation with the highest
level of Y783 residue phosphorylation occurring at 2min
(Figure 5(a)). Preincubation of ECV304 cells with PTX or apoc-
ynin prevents PLC-γ1 (Y783) phosphorylation (Figure 5(b)),
suggesting that PLC-γ1 activation depends on FPR1 stimula-
tion and NADPH oxidase-dependent ROS generation.
PLC-γ1 catalyzes the hydrolysis of the phos-
phatidylinositol (4,5)-bisphosphate (PIP2), which results in
the production of diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). IP3 triggers the release of calcium from
endoplasmic reticulum and, therefore, an increase in its
intracellular concentration, whereas DAG activates protein
kinase C (PKC). The PKC isoenzymes PKCα, PKCβ, and
PKCζ are implicated in VEGF-mediated signalling [41, 56].
In N-fMLP-stimulated ECV304 cells, we investigated the
activation of PKC isoenzymes by analyzing their membrane
translocation. We observed that in response to the FPR1 ago-
nist, PKCα, PKCβΙΙ, and PKCζ translocate to the membrane
and a substantial increment in their amount was found
within 2min of N-fMLP treatment. On the other hand, we
did not observe PKCδ translocation (Figure 5(c)).
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Figure 3: Flk-1/KDR transactivation depends on NADPH oxidase activation. (a) Serum-starved ECV304 cells were stimulated with 0.1 μM
N-fMLP for 5minutes in the presence or absence of 100 μMapocynin, or (b) ECV304 cells serum-deprived for 24 hours were incubated for 12
hours with 5 nM siRNA against p22phox (p22phox siRNA) or negative control siRNA (NC siRNA) in DMEM containing 10% FBS in the
presence of 20μl of HiPerfect and stimulated with 0.1μM N-fMLP for 5 minutes. Fifty micrograms of whole lysates were resolved on 10%
SDS-PAGE and immunoblotted with α-pFlk-1 (Y951), α-pFlk-1 (Y996), α-pFlk-1 (Y1175), α-pFlk-1 (Y1214), or α-p22phox antibodies.
An α-Flk-1 antibody served as a control for protein loading. All the experiments are representative of at least three independent
experiments. ∗p < 0 05 compared with unstimulated cells. °p < 0 05 compared with unstimulated cells. #p < 0 05 compared with
unstimulated cells. $p < 0 05 compared with unstimulated cells.
7Oxidative Medicine and Cellular Longevity
2′ 5′ 10′−
N-fMLP
pPI3K (p85) WB: 훼-pPI3K (p85)
Tubulin WB: 훼-tubulin
2′ 5′ 10′−
N-fMLP
⁎
⁎
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(a)
pPI3K (p85) WB: 훼-pPI3K (p85)
Tubulin WB: 훼-tubulin
N-fMLP (0.1 휇M)
PTX (100 ng/ml)
Apocynin (100 휇M)
−
+
−
+
+
+
− +
−
− − −
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(b)
2′ 5′ 10′−
N-fMLP
pAkt (Ser473) WB: 훼-pAkt (Ser473)
Tubulin WB: 훼-tubulin
2′ 5′ 10′−
N-fMLP
⁎
⁎
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(c)
pAkt (Ser473) WB: 훼-pAkt (Ser473) 
Tubulin WB: 훼-tubulin
−
−
−
−
+
− +
N-fMLP (0.1 휇M)
Wortmannin (0.5 휇M)
LY294002 (50 휇M)
−
− ++ +
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(d)
pAkt (Ser473) WB: 훼-pAkt (Ser473)
Tubulin WB: 훼-tubulin
−
−
−
−
+
− +
N-fMLP (0.1 휇M)
PTX (100 ng/ml) 
Apocynin (100 휇M)
−
++ +−
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(e)
pAkt (Ser473) WB: 훼-pAkt (Ser473)
Tubulin WB: 훼-tubulin
−
−
+
−
−
+
− +
− N-fMLP (0.1 휇M)
FPR1 siRNA (5 nM)
NC siRNA (5 nM)
−
+
+
⁎
⁎
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(f)
WB: 훼-p22phox p22phox
pAkt (Ser473) WB: 훼-pAkt (Ser473) 
Tubulin WB: 훼-tubulin
−
−
+
−
−
+
−
N-fMLP (0.1 휇M)
p22phox siRNA (5 nM)
NC siRNA (5 nM) 
−
+
+
−
−
⁎
° ⁎ °
p22phox
pAkt (Ser473)
0
20
40
60
80
100
Re
la
tiv
e
ph
os
ph
or
yl
at
io
n
(%
)
(g)
Figure 4: FPR1-mediated Flk-1/KDR transactivation triggers the PI3K-Akt pathway. (a, c) Cell lysates were puriﬁed from serum-starved
ECV304 cells exposed to 0.1 μM N-fMLP for the indicated times. (b, e) ECV304 cells were serum-deprived for 24 hours before the
stimulation for 5 minutes with N-fMLP in the absence or presence of PTX, apocynin, (d) wortmannin, or LY294002. (f) ECV304 cells were
serum-deprived for 24 hours, incubated for 12 hours with 5 nM siRNA against FPR1 (FPR1 siRNA) or (g) against p22phox (p22phox siRNA)
or negative control siRNA (NC siRNA), in DMEM containing 10% FBS in the presence of 20μl of HiPerfect, and stimulated with 0.1μM
N-fMLP for 5 minutes. Fifty micrograms of whole lysates was resolved on 10% SDS-PAGE and immunoblotted with (a, b) an α-pPI3K (p85)
or (c–g) an α-pAkt (S473) antibody. An α-tubulin antibody served as a control for protein loading. All the experiments are representative
of at least three independent experiments. ∗p < 0 05 compared with unstimulated cells. °p < 0 05 compared with unstimulated cells.
8 Oxidative Medicine and Cellular Longevity
3.6. FPR1 Stimulation by N-fMLP Promotes Wound
Healing and Capillary-Like Network Formation. Endothe-
lial cell migration is a very critical event during the angio-
genesis process. In tumor angiogenesis, endothelial cells
invade the surrounding basement membrane and migrate
into the stroma. Finally, they organize themselves in the
formation of new blood capillaries, which are crucial for
tumor growth.
Several signalling cascades are implicated in Flk-1/
KDR-mediated migration. These involve Y1175 residue
phosphorylation and, in turn, the activation of PI3K, as
well as the phosphorylation of the Y951 residue, which is
a binding site for TSAd [41]. To assess whether FPR1 stim-
ulation by N-fMLP induces cell migration, thus promoting
wound closure, we tested ECV304 cells in an in vitro wound
healing assay. Our results show that N-fMLP induces a
more rapid cell migration with respect to unstimulated
cells, after both 24 and 36 hours (Figure 6(a)). The prein-
cubation with PTX, before stimulation, prevents N-fMLP-
induced wound closure (Figure 6(a)), suggesting that it
depends on FPR1 activation.
We also assessed the eﬀects of N-fMLP on capillary-like
network formation in a Matrigel assay, which is considered
an in vitro correlate of angiogenesis. The level of capillary-
like network formation was analyzed by measuring the tube
length after 1 day of culture. Cells incubated with 20ng/ml
VEGF were used as a control. As shown in Figure 6(b),
FPR1 stimulation by N-fMLP results in a signiﬁcant increase
in capillary-like network formation, which is prevented by
preincubation with PTX. The tube lengths were substantially
increased also in control ECV304 cells exposed to VEGF,
compared to untreated cells (Figure 6(b)).
4. Conclusions
We demonstrate that, in ECV304 cells, FPR1 stimulation
by N-fMLP results in NADPH oxidase-dependent ROS
production and VEGFR2 transphosphorylation. Moreover,
we demonstrate that ROS bridge the signals from FPR1
to Flk-1/KDR, as evidenced by the results obtained with
apocynin and with p22phox silencing on VEGFR2 transacti-
vation and on the intracellular signalling cascades elicited
by this receptor. We also show that, as a result of the transac-
tivation mechanism, phosphotyrosines Y951, Y996, and
Y1175 of VEGFR2 create anchoring sites for the enrollment
and activation of the PI3K/Akt and PLC-γ/PKC pathways,
fostering some of the molecular responses elicited by
VEGFA. Finally, we prove that the FPR1-induced signalling
promotes cellular migration and capillary-like network for-
mation of ECV304 cells.
GPCRs represent the largest family of drug targets,
which can bind to receptors with high selectivity and reg-
ulate several functions in a predictable manner. The obser-
vation that each GPCR can engage multiple signalling
partners, driving multiple cellular responses, leads to the
concept that diﬀerent ligands can have distinct eﬃcacies
toward these diﬀerent pathways.
GPCRs can trigger signalling cascades in a ligand-speciﬁc
manner and can cross-talk with RTKs by amplifying intra-
cellular signalling pathways. NADPH oxidase-derived ROS
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Figure 5: Tyrosine phosphorylation of 1175 residues of Flk-1/KDR triggers the PLC-γ1/PKC pathway. (a, c) Serum-deprived ECV304 cells
were stimulated with 0.1 μMN-fMLP for the indicated times or (b) for 5 minutes in the presence or absence of PTX or apocynin. (a, b) Fifty
micrograms of whole lysates was resolved on 10% SDS-PAGE, and PLCγ1 phosphorylation on the Y783 residue was detected by using an α-
pPLCγ1 (Y783) antibody. An α-PLCγ1 antibody was used as a control for protein loading. (c) Membrane proteins (50 μg) were resolved on
10% SDS-PAGE, and PKC isoforms were detected by using the speciﬁc antibodies α-PKCα, α-PKCβII, α-PKCζ, or α-PKCδ as indicated. All
the experiments are representative of at least three independent experiments. ∗p < 0 05 compared with unstimulated cells.
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act as signalling molecules by reversible oxidative inactiva-
tion of cysteine sulfhydryl groups of PTPs, which can, in
turn, control the activity of RTKs and their transactivation
[19, 20, 24]. Phosphorylation of cytosolic subunits p47phox
and p67phox is required for NADPH oxidase activation. Our
results show that ROS generation by NADPH oxidase is
tightly regulated and depends on FPR1 stimulation by N-
fMLP, which triggers p47phox phosphorylation and, in turn,
superoxide generation. The ﬁnding that ROS mediate
Flk-1/KDR transactivation, playing a crucial role in VEGFR2
signalling related to angiogenesis, provides new insights
into NADPH oxidase and/or FPR1 as possible targets for
therapies against angiogenesis-dependent diseases. The
identiﬁed antiangiogenic drugs targeting the VEGFR2 sig-
nalling pathways are shared by several RTKs that do not
evoke angiogenesis, and the actual antiangiogenic therapies,
which target either VEGFA action or Flk-1/KDR activity,
may induce the upregulation of other RTKs to overcome
the VEGFR blockade. Cross-talk between FPR1 and Flk-1/
KDR provides further opportunities for drug discovery
strategies for angiogenesis driven by an increase in
VEGFR2 activity, disputing actual thinking in the notion
of pharmacological targets. Elucidation of the signalling
cascades responsible for VEGFR2 transactivation can con-
tribute to the identiﬁcation of new therapeutic targets able
to interfere with the FPR1 pathway. Furthermore, our results
suggest that targeting both FPR1 and VEGFR2might provide
improved therapeutic eﬀects, compared to targeting either
receptor distinctively.
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Figure 6: Wound healing and capillary-like network formation induced by FPR1. (a) Representative images (left) and bar graph
quantiﬁcation (right) of ECV304 cell migration from 5 independent experiments. Cells were incubated with 0.1 μM N-fMLP or vehicle in
the presence or absence of PTX. Images were acquired at diﬀerent times (0, 24, and 36 hours) after wound injury (scale bar: 20μm). (b)
Capillary-like network formation (left) was performed in Matrigel-coated plates. ECV304 cells were incubated with N-fMLP in the
presence or absence of PTX, and bar graphs (right) show the quantiﬁcation of relative tube length from four independent experiments.
Cells incubated with VEGF (20 μg/ml) were used as a positive control (scale bar: 50μm). ∗p < 0 05 compared with unstimulated cells.
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